Clinical trials in Mannheim – page 5

357 clinical trials in Mannheim, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Mannheim at a glance

357

clinical trials

Research sites2

Quick filters

357 trials in Mannheim

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Erdafitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Vorasidenib
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Gastrooesophageal cancer+1

Recruiting

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fruquintinib
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Immune thrombocytopenia

Recruiting

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Mezagitamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Penile squamous cell carcinoma

Recruiting

Study of enfortumab vedotin and avelumab for patients with advanced or metastatic penile cancer that has spread or cannot be removed by surgery

Registered drugNo placebo

Study of enfortumab vedotin and avelumab for patients with advanced or metastatic penile cancer that has spread or cannot be removed by surgery

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Avelumab
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Immune thrombocytopenia

Recruiting

A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

Investigational

A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Mezagitamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Desmoid tumour

Recruiting

Study of nirogacestat in adult premenopausal women with desmoid tumors and aggressive fibromatosis to evaluate ovarian function recovery

InvestigationalNo placebo

Study of nirogacestat in adult premenopausal women with desmoid tumors and aggressive fibromatosis to evaluate ovarian function recovery

InvestigationalNo placebo

Germany

Participants:18–64 years
Substances:Nirogacestat Hydrobromide
Sponsor:Springworks Therapeutics Inc.

Contact Research Centre

Adenocarcinoma pancreas+1

Recruiting

Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

Registered drugNo placebo

Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Mannheim

What the registry says about research in the country

01 Neurodegenerative Disorders

Clinical investigations focusing on Alzheimer's Disease and ALS, including trials of new therapeutic compounds for early-stage dementia and innovative treatments for motor neuron disease.

Early-stage Alzheimer's diagnostic tools
Novel drug therapies for neurodegenerative conditions
Disease progression monitoring

Research aims to improve brain amyloid clearance and evaluate new treatment approaches for neurological disorders.

02 Oncology Research

Comprehensive studies in cancer treatment, including trials for gastric cancer, melanoma, and breast cancer, with a focus on targeted therapies and immunological approaches.

HER2-expressing cancers
Metastatic melanoma treatments
Lymphoma therapies

Advanced treatments combining immunotherapy with established protocols to improve patient outcomes.

03 Inflammatory Conditions

Studies addressing inflammatory disorders, particularly focusing on Crohn's Disease, ulcerative colitis, and uveitis, testing novel therapeutic combinations.

Gastrointestinal disorders
Autoimmune conditions
Combination therapy approaches

Innovative treatment strategies aimed at improving disease management and patient quality of life.

Back to Germany All countries